November 1, 2017
On November 1, 2017, ANGLE PLC (AIM: AGL) (OTCQX: ANPCY), a world-leading liquid biopsy company, announced that it had completed its previously announced acquisition of certain assets of Axela Inc., a Canadian firm with intellectual property that complements ANGLE’s Parsortix liquid biopsy platform.
ANGLE paid $6.16 million for the assets and eight members of the Axela team will be moving on to ANGLE’s payroll.
Miller Thomson advised ANGLE in this acquisition with a team that included Eamonn Flaherty (corporate), Jeff Carhart (insolvency), Karen Durell (IP) and David Tsai (employment).
